OnCo
drugsProductNegative

Rindopepimut

A vaccine against a glioblastoma-specific mutant protein that looked promising for years and then failed its phase 3 trial in 2016. It is a landmark failure.

EGFRvIII peptide conjugated to KLH with GM-CSF. Phase 2 (ACT III) suggested prolonged survival versus historical controls; the double-blind phase 3 ACT IV (n=745, EGFRvIII-positive newly diagnosed glioblastoma with minimal residual disease) showed no OS benefit (20.1 vs 20.0 months). Loss of EGFRvIII expression at recurrence in both arms illustrated antigen escape. Celldex discontinued the programme.

Schematic of the modality · Peptide vaccine (EGFRvIII) · not a molecule; see the Off-the-shelf cancer vaccines page
Modality
Peptide vaccine (EGFRvIII)
Mechanism
Induces humoral and cellular immunity against the EGFRvIII neoepitope.
Brand / code
CDX-110

Trials

top
ClinicalTrials.gov · phase 2/3
refreshed 2026-09-09
3 studies0 recruiting2 Phase 21 Phase 3
Search “Rindopepimut” on ClinicalTrials.gov →
Counts are from a name search and may include unrelated studies; up to 100 studies are summarised.

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
Rindopepimut
intervention: Rindopepimut
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Landmark trials in OnCo

Latest papers

top
Literature trend0 papers in the last 12 monthsHow this is computed
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"Rindopepimut" OR ABSTRACT:"Rindopepimut" OR TITLE:"CDX-110" OR ABSTRACT:"CDX-110") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Rindopepimut, not a curated reading list.

Connected

6top